The Centers for Medicare & Medicaid Services (CMS) reportedly will collect information from hospitals about the prices they pay for drugs through the 340B discount program.

How will the information gathered by CMS be used, moving forward? And why is this action being taken by CMS? The agency has a history of attempted cuts to 340B reimbursement; the most recent such action by CMS occurred last December, after which a federal judge ruled against the move.

Reporting our lead story during this edition of Monitor Mondays is Maureen Testoni, president and CEO of 340B Health.

Other segments featured on this episode include:

• Court Report: Federal law enforcement personnel recently took down a fraudulent scheme involving 35 defendants associated with telemedicine companies and cancer genetic testing laboratories. The defendants have been charged for their alleged participation in fraudulently billing Medicare more than $2.1 billion for CGx tests. Reporting this story is famed whistleblower attorney Mary Inman, a partner in the London office of Constantine Cannon.
  
  
• RAC Report: Healthcare attorney Knicole Emanuel reports on the latest audits by Recovery Audit Contractors (RACs) and other third-party auditors. Emanuel, a member of the RACmonitor editorial board, is a partner in the Potomac Law Group.
  
  
• SDoH Report: Ellen Fink-Samnick, a nationally recognized expert on the social determinants of health (SDoH), has the latest news on this trending topic that is attracting significant media attention. Ellen also conducts the Monitor Mondays Listener Survey.
  
  
• Risky Business: Healthcare attorney David Glaser returns to Monitor Mondays to report on problematic issues facing providers.
  
  
• Monday Rounds: Ronald Hirsch, MD, vice president of R1 RCM, makes his Monday Rounds with another installment of his popular segment.